CoChat

Targeting inflammation in diabetic kidney disease: early clinical trials

Perez-Gomez, Maria Vanessa, Sanchez-Niño, Maria Dolores, Sanz, Ana Belen, Zheng, Binbin, Martín-Cleary, Catalina, Ruiz-Ortega, Marta, Ortiz, Alberto, Fernandez-Fernandez, Beatriz · 2016 · Expert Opinion on Investigational Drugs
Cited by 78

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The age-standardized death rate from diabetic kidney disease increased by 106% from 1990 to 2013, indicating that novel therapeutic approaches are needed, in addition to the renin-angiotensin system (RAS) blockers currently in use. Clinical trial results of anti-fibrotic therapy have been disappointing. However, promising anti-inflammatory drugs are currently on phase 1 and 2 randomized controlled trials. AREAS COVERED: The authors review the preclinical, phase 1 and 2 clinical trial information of drugs tested for diabetic kidney disease that directly target inflammation as a main or key mode of action. Agents mainly targeting other pathways, such as endothelin receptor or mineralocorticoid receptor blockers and vitamin D receptor activators are not discussed. EXPERT OPINION: Agents targeting inflammation have shown promising results in the treatment of diabetic kidney disease when added on top of RAS blockade. The success of pentoxifylline in open label trials supports the concept of targeting inflammation. In early clinical trials, the pentoxifylline derivative CTP-499, the CCR2 inhibitor CCX140-B, the CCL2 inhibitor emapticap pegol and the JAK1/JAK2 inhibitor baricitinib were the most promising drugs for diabetic kidney disease. The termination of trials testing the anti-IL-1β antibody gevokizumab in 2015 will postpone the evaluation of therapies targeting inflammatory cytokines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13543784.2016.1196184

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 78

Metadata

Authors
Perez-Gomez, M. V., Sanchez-Niño, M. D., Sanz, A. B., Zheng, B., Martín-Cleary, C., Ruiz-Ortega, M., Ortiz, A., & Fernandez-Fernandez, B.
Venue
Expert Opinion on Investigational Drugs
Published
2016-06-13
Volume
25
Issue
9
Pages
1045-1058
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2417738757
Cited by
78
References
14
FWCI
10.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting inflammation in diabetic kidney disease: early clinical trials. https://app.cochat.ai/papers/10.1080/13543784.2016.1196184
The paper
Perez-Gomez, M. V., Sanchez-Niño, M. D., Sanz, A. B., Zheng, B., Martín-Cleary, C., Ruiz-Ortega, M., Ortiz, A., & Fernandez-Fernandez, B. (2016). Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2016.1196184

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.